Summary
Superior performance of SPEAR UltraDetect™ pTau 231
Early and accurate detection of Alzheimer’s disease pathology is critical for advancing therapeutic development and improving patient outcomes. pTau 231 has been shown to strongly associate with the earliest cerebral amyloid-beta (Aβ) changes, with plasma pTau 231 becoming abnormal at preclinical stages with the lowest Aβ burden. These data present pTau 231 as a strong candidate biomarker for early Alzheimer’s detection and for tracking longitudinal Aβ changes in clinical studies.
How does the SPEAR UltraDetect™ pTau 231 Assay compare to other assays?
In this application note, the analytical performance of SPEAR UltraDetect™ pTau 231 Assay is compared with a competitor’s assay. The SPEAR Assay demonstrates higher sensitivity and precision, achieving 100% detection and 100% quantification in healthy individuals in addition to:
- Robust quantification of baseline and subthreshold changes in pTau 231 levels.
- Unlocking the potential of pTau 231 as a plasma biomarker for early detection and longitudinal tracking of disease progression.
Learn more about SPEAR UltraDetect Assays distributed by Bio-Techne.
Request Literature
To access this literature content please fill out the form below.